Multi-Chemotherapeutic Schedules Containing the pan-FGFR Inhibitor ARQ 087 are Safe and Show Antitumor Activity in Different Xenograft Models()

Por Chilà, Rosaria, Hall G., Terence, Abbadessa, Giovanni, Broggini, Massimo, Damia, Giovanna
Publicado no Transl Oncol (2017)

Combination of the c-Met Inhibitor Tivantinib and Zoledronic Acid Prevents Tumor Bone Engraftment and Inhibits Progression of Established Bone Metastases in a Breast Xenograft Mode...

Por Previdi, Sara, Scolari, Federica, Chilà, Rosaria, Ricci, Francesca, Abbadessa, Giovanni, Broggini, Massimo
Publicado em 2013

Optimized management of advanced hepatocellular carcinoma: Four long-lasting responses to sorafenib

Por Abbadessa, Giovanni, Rimassa, Lorenza, Pressiani, Tiziana, Carrillo-Infante, Cynthia, Cucchi, Emanuele, Santoro, Armando
Publicado em 2011

In-vitro and in-vivo combined effect of ARQ 092, an AKT inhibitor, with ARQ 087, a FGFR inhibitor

Por Yu, Yi, Hall, Terence, Eathiraj, Sudharshan, Wick, Michael J., Schwartz, Brian, Abbadessa, Giovanni
Publicado no Anticancer Drugs (2017)

In vivo efficacy of the AKT inhibitor ARQ 092 in Noonan Syndrome with multiple lentigines-associated hypertrophic cardiomyopathy

Por Wang, Jianxun, Chandrasekhar, Vasanth, Abbadessa, Giovanni, Yu, Yi, Schwartz, Brian, Kontaridis, Maria I.
Publicado no PLoS One (2017)

Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092

Por Yu, Yi, Savage, Ronald E., Eathiraj, Sudharshan, Meade, Justin, Wick, Michael J., Hall, Terence, Abbadessa, Giovanni, Schwartz, Brian
Publicado no PLoS One (2015)

Preclinical Activity of ARQ 087, a Novel Inhibitor Targeting FGFR Dysregulation

Por Hall, Terence G., Yu, Yi, Eathiraj, Sudharshan, Wang, Yunxia, Savage, Ronald E., Lapierre, Jean-Marc, Schwartz, Brian, Abbadessa, Giovanni
Publicado no PLoS One (2016)

Alternative stabilities of a proline-rich antibacterial peptide in vitro and in vivo

Por Noto, Paul Bart, Abbadessa, Giovanni, Cassone, Marco, Mateo, George D., Agelan, Alexis, Wade, John D., Szabo, Dora, Kocsis, Bela, Nagy, Karoly, Rozgonyi, Ferenc, Otvos, Laszlo
Publicado em 2008

ARQ 092, an orally-available, selective AKT inhibitor, attenuates neutrophil-platelet interactions in sickle cell disease

Por Kim, Kyungho, Li, Jing, Barazia, Andrew, Tseng, Alan, Youn, Seock-Won, Abbadessa, Giovanni, Yu, Yi, Schwartz, Brian, Andrews, Robert K., Gordeuk, Victor R., Cho, Jaehyung
Publicado no Haematologica (2017)

Combination of AKT inhibitor ARQ 092 and sorafenib potentiates inhibition of tumor progression in cirrhotic rat model of hepatocellular carcinoma

Por Jilkova, Zuzana Macek, Kuyucu, Ayca Zeybek, Kurma, Keerthi, Ahmad Pour, Séyédéh Tayébéh, Roth, Gaël S., Abbadessa, Giovanni, Yu, Yi, Schwartz, Brian, Sturm, Nathalie, Marche, Patrice N., Hainaut, Pierre, Decaens, Thomas
Publicado no Oncotarget (2018)

Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab

Por Martin, Thomas G., Corzo, Kathryn, Chiron, Marielle, van de Velde, Helgi, Abbadessa, Giovanni, Campana, Frank, Solanki, Malini, Meng, Robin, Lee, Helen, Wiederschain, Dmitri, Zhu, Chen, Rak, Alexey, Anderson, Kenneth C.
Publicado no Cells (2019)

Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trial

Por Rimassa, Lorenza, Porta, Camillo, Borbath, Ivan, Daniele, Bruno, Finn, Richard S, Raoul, Jean-Luc, Schwartz, Lawrence H, He, Aiwu Ruth, Trojan, Joerg, Peck-Radosavljevic, Markus, Abbadessa, Giovanni, Goldberg, Terri, Santoro, Armando, Bruix, Jordi
Publicado no Hepat Oncol (2014)

Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma

Por Rimassa, Lorenza, Reig, Maria, Abbadessa, Giovanni, Peck-Radosavljevic, Markus, Harris, William, Zagonel, Vittorina, Pastorelli, Davide, Rota Caremoli, Elena, Porta, Camillo, Damjanov, Nevena, Patel, Hitendra, Daniele, Bruno, Lamar, Maria, Schwartz, Brian, Goldberg, Terri, Santoro, Armando, Bruix, Jordi
Publicado no World J Gastroenterol (2017)

Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma

Por Personeni, Nicola, Giordano, Laura, Abbadessa, Giovanni, Porta, Camillo, Borbath, Ivan, Daniele, Bruno, Laethem, Jean-Luc Van, Vlierberghe, Hans Van, Trojan, Jörg, De Toni, Enrico N., Gasbarrini, Antonio, Lencioni, Monica, Lamar, Maria E., Wang, Yunxia, Shuster, Dale, Schwartz, Brian, Santoro, Armando, Rimassa, Lorenza
Publicado no Oncotarget (2017)

Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib

Por Rimassa, Lorenza, Abbadessa, Giovanni, Personeni, Nicola, Porta, Camillo, Borbath, Ivan, Daniele, Bruno, Salvagni, Stefania, Van Laethem, Jean-Luc, Van Vlierberghe, Hans, Trojan, Jörg, De Toni, Enrico N., Weiss, Alan, Miles, Steven, Gasbarrini, Antonio, Lencioni, Monica, Lamar, Maria E., Wang, Yunxia, Shuster, Dale, Schwartz, Brian E., Santoro, Armando
Publicado no Oncotarget (2016)

The new small tyrosine kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs

Por Soncini, Debora, Orecchioni, Stefania, Ruberti, Samantha, Minetto, Paola, Martinuzzi, Claudia, Agnelli, Luca, Todoerti, Katia, Cagnetta, Antonia, Miglino, Maurizio, Clavio, Marino, Contini, Paola, Varaldo, Riccardo, Bergamaschi, Micaela, Guolo, Fabio, Passalacqua, Mario, Nencioni, Alessio, Monacelli, Fiammetta, Gobbi, Marco, Neri, Antonino, Abbadessa, Giovanni, Eathiraj, Sudharshan, Schwartz, Brian, Bertolini, Francesco, Lemoli, Roberto M., Cea, Michele
Publicado no Haematologica (2019)

The BTK Inhibitor ARQ 531 Targets Ibrutinib Resistant CLL and Richter’s Transformation

Por Reiff, Sean D., Mantel, Rose, Smith, Lisa L., Greene, JT, Muhowski, Elizabeth M., Fabian, Catherine A., Goettl, Virginia M., Tran, Minh, Harrington, Bonnie K., Rogers, Kerry A., Awan, Farrukh T., Maddocks, Kami, Andritsos, Leslie, Lehman, Amy M., Sampath, Deepa, Lapalombella, Rosa, Eathiraj, Sudharshan, Abbadessa, Giovanni, Schwartz, Brian, Johnson, Amy J., Byrd, John C., Woyach, Jennifer A.
Publicado no Cancer Discov (2018)